Deep Remission Tied to RA Control - Summary - MDSpire
From the Journals

Deep Remission Tied to RA Control

At 5 years, 63% of patients in the CliDR group maintained sustained remission compared with 38% in the non-CliDR group.

  • By

  • Andrea Surnit

  • May 6, 2026

  • 4 min

Share

In a recent study published in RMD Open, researchers found that patients with rheumatoid arthritis (RA) who achieved clinical deep remission (CliDR) were more successful in maintaining long-term remission and exhibited reduced relapse rates compared to those meeting less stringent remission criteria. Out of 145 patients analyzed over five years, 63% in the CliDR group maintained sustained remission, while only 38% of the non-CliDR group did. The investigation highlights the significance of remission depth in evaluating treatment tapering strategies in RA management.

Original Source(s)

Deep Remission Tied to RA Control

  • by Andrea Surnit

  • May 6, 2026

Related Content

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

Tofacitinib vs Adalimumab Findings Require Caution in RA

Meta-analysis favored tofacitinib for some rheumatoid arthritis outcomes, but high heterogeneity, dose-dependent effects, and JAK inhibitor safety concerns complicate interpretation.

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.